For this purpose, we analyzed the prognostic value of PRMT5 or MEP50 mRNA in the two subpopulations expressing high (> median) or low (< median) MEP50 or PRMT5 mRNA levels in the different breast cancer subgroups. This evidence concerns the gene PRMT5 and breast carcinoma.